Back to Search Start Over

Clinical and biological aspects of myeloid leukemia in Down syndrome

Authors :
Boucher, Austin C.
Caldwell, Kenneth J.
Crispino, John D.
Flerlage, Jamie E.
Source :
Leukemia; 20240101, Issue: Preprints p1-9, 9p
Publication Year :
2024

Abstract

Children with Down syndrome are at an elevated risk of leukemia, especially myeloid leukemia (ML-DS). This malignancy is frequently preceded by transient abnormal myelopoiesis (TAM), which is self-limited expansion of fetal liver-derived megakaryocyte progenitors. An array of international studies has led to consensus in treating ML-DS with reduced-intensity chemotherapy, leading to excellent outcomes. In addition, studies performed in the past 20 years have revealed many of the genetic and epigenetic features of the tumors, including GATA1mutations that are arguably associated with all cases of both TAM and ML-DS. Despite these advances in understanding the clinical and biological aspects of ML-DS, little is known about the mechanisms of relapse. Upon relapse, patients face a poor outcome, and there is no consensus on treatment. Future studies need to be focused on this challenging aspect of leukemia in children with DS.

Details

Language :
English
ISSN :
08876924 and 14765551
Issue :
Preprints
Database :
Supplemental Index
Journal :
Leukemia
Publication Type :
Periodical
Accession number :
ejs57821084
Full Text :
https://doi.org/10.1038/s41375-021-01414-y